FDA Issues Complete Response Letter to Supernus for SPN-830, a Potential Treatment for Motor Fluctuations in Parkinson Disease

Posted on April 8, 2024 by admin

According to the letter, the FDA believes that the investigational apomorphine infusion device is not ready for approval in its current form.